Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs MultiMedRx

Maves
Graded #91

Higher grade

vs+13.999999999999993
MultiMedRx
Graded #394

Lower grade

The verdict

Maves takes it — 71.6/100 to 57.6/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +38
83
45
Dose & formulationMaves +12
65
53
Clinical oversightMultiMedRx +3
76
79
Labs & monitoringMultiMedRx +1
52
53
FulfillmentMaves +20
87
67
Contract termsMaves +6
55
49
Maves · left barMultiMedRx · right bar

The numbers

MetricMavesMultiMedRx
WeighScore71.6/10057.6/100
GradeCC
Scorecard rank#91#394
Semaglutide$99/mo (starting dose, first-month rate, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Maves

Graded #91 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
MultiMedRx

Graded #394 · C

Strengths

  • Legal entity disclosed (MMRX MultiMedRx LLC) — uncommon transparency
  • Two physical addresses listed: Newport Beach, CA and Reno, NV
  • LegitScript seal present
  • Features brand-name GLP-1s (Ozempic, Wegovy, Zepbound) — rare in a mostly compounded-only field
  • Broader cardiometabolic menu (metformin, testosterone, HRT) alongside GLP-1

Where it loses points

  • No Mounjaro or Foundayo in the brand-name lineup (only Ozempic, Wegovy, Zepbound)
  • Monthly GLP-1 pricing isn't published — gated behind the consultation
  • $100 consultation fee adds friction; many peers bundle it into the medication price
  • Per-state availability not listed; only CA and NV offices disclosed
  • Whether compounded GLP-1 is offered isn't clear — verify during intake

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard